Your browser is no longer supported. Please, upgrade your browser.
Settings
CLLS Cellectis S.A. daily Stock Chart
CLLS [NASD]
Cellectis S.A.
Index- P/E- EPS (ttm)-2.11 Insider Own- Shs Outstand41.36M Perf Week-15.81%
Market Cap898.34M Forward P/E- EPS next Y-2.01 Insider Trans- Shs Float31.33M Perf Month-17.10%
Income-82.30M PEG- EPS next Q-0.62 Inst Own34.60% Short Float2.12% Perf Quarter-25.79%
Sales25.80M P/S34.82 EPS this Y-46.00% Inst Trans4.97% Short Ratio4.20 Perf Half Y-28.93%
Book/sh10.15 P/B2.14 EPS next Y-4.00% ROA-18.80% Target Price46.78 Perf Year-8.51%
Cash/sh- P/C- EPS next 5Y- ROE-23.00% 52W Range21.29 - 38.85 Perf YTD-25.49%
Dividend- P/FCF- EPS past 5Y-36.40% ROI-35.00% 52W High-44.09% Beta1.73
Dividend %- Quick Ratio11.20 Sales past 5Y15.50% Gross Margin-13.50% 52W Low2.02% ATR0.96
Employees135 Current Ratio11.20 Sales Q/Q-69.90% Oper. Margin- RSI (14)21.37 Volatility4.82% 3.30%
OptionableYes Debt/Eq0.00 EPS Q/Q27.40% Profit Margin- Rel Volume1.88 Prev Close22.00
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume157.84K Price21.72
Recom1.80 SMA20-14.76% SMA50-19.11% SMA200-25.77% Volume291,015 Change-1.27%
Jul-16-18Initiated Barclays Overweight $50
Mar-16-18Initiated Guggenheim Neutral
Sep-05-17Reiterated Wells Fargo Outperform $33 → $40
Sep-05-17Downgrade SunTrust Buy → Hold
Mar-02-17Initiated Instinet Buy $49
Feb-28-17Initiated Wells Fargo Outperform
Apr-05-16Initiated Ladenburg Thalmann Buy $45
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15Initiated BofA/Merrill Buy $50
Apr-20-15Initiated Piper Jaffray Overweight $42
Apr-20-15Initiated Jefferies Buy $46
Nov-13-18 04:30PM  Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 Business Wire
Oct-17-18 08:10AM  New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Sep-19-18 04:30PM  CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board Business Wire
Sep-18-18 04:30PM  Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP Business Wire
Aug-20-18 07:40AM  Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-02-18 04:30PM  Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer Business Wire
Aug-01-18 04:30PM  Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 Business Wire
Jun-27-18 04:30PM  Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 Business Wire
Jun-12-18 04:30PM  Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports Business Wire
Jun-08-18 09:56AM  Should Cellectis SA.s (NASDAQ:CLLS) Recent Earnings Decline Worry You? Simply Wall St.
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-04-18 04:30PM  FDA Grants Cellectis IND Approval for UCART22 in B-ALL Business Wire
May-22-18 07:59PM  INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
04:30PM  Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
May-21-18 08:30AM  Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-15-18 05:50PM  Calyxt Announces Launch of Proposed Follow-On Offering Business Wire
May-10-18 05:15PM  Cellectis to Present Data at the 2018 ASGCT Annual Meeting Business Wire
07:30AM  Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies ACCESSWIRE
May-07-18 04:30PM  Cellectis Reports 1st Quarter 2018 Financial Results Business Wire
May-02-18 04:30PM  Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) Business Wire
May-01-18 07:01AM  George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome Forbes
07:00AM  Harvards Wyss Institute Partners with Cellectis to Recode the Human Genome Business Wire
Apr-18-18 01:37AM  Should Cellectis SA.s (EPA:ALCLS) Recent Earnings Decline Worry You? Simply Wall St.
Apr-13-18 08:15AM  What Should We Expect From Cellectis SA.s (NASDAQ:CLLS) Earnings Over The Next Few Years? Simply Wall St.
Apr-11-18 07:40AM  Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide Fundamental Analysis, Key Performance Indications GlobeNewswire
01:50AM  Cellectis to Present Data at the 2018 AACR Annual Meeting Business Wire
Apr-10-18 04:10PM  Cellectis Announces Closing of Follow-On Offering Business Wire
Apr-07-18 08:34AM  Is Cellectis SA Stock a Buy Now? Motley Fool
Apr-06-18 08:45AM  Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again? Motley Fool
Apr-05-18 04:34PM  Why Micron Technology, Mechel, and Cellectis Slumped Today Motley Fool -12.39%
08:05AM  Could Orgenesis (ORGS) be the Next Acquisition Target in Cell Therapy Space? ACCESSWIRE
Apr-04-18 08:30PM  Cellectis Announces Pricing of Follow-On Offering Business Wire -14.09%
Apr-03-18 05:45PM  Cellectis Announces Launch of Follow-On Offering Business Wire +25.38%
04:09PM  Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs Investor's Business Daily
01:14PM  Pfizer in deal with Allogene to develop cancer cell therapies Reuters
08:10AM  Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies Business Wire
Mar-19-18 03:06AM  What Should Investors Know About Cellectis SA.s (EPA:ALCLS) Earnings Trend? Simply Wall St.
Mar-16-18 02:33PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-13-18 04:30PM  Dr. Mathieu Simon to Retire as Cellectis Chief Operating Officer; Elsy Boglioli Named as Successor Business Wire
08:22AM  Cellectis SA.s (NASDAQ:CLLS) Profit Outlook Simply Wall St.
Mar-12-18 04:51PM  Cellectis Reports 4th Quarter and Full Year 2017 Financial Results Business Wire
Mar-08-18 04:30PM  Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting Business Wire
Mar-05-18 12:00AM  [$$] Crispr gene editing ready for testing in humans Financial Times
Feb-13-18 12:01AM  Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells Business Wire
12:00AM  France's Cellectis wins U.S patents for gene editing technology Reuters
Jan-02-18 04:30PM  Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT Business Wire
Dec-26-17 11:22AM  ETFs with exposure to Cellectis SA : December 26, 2017 Capital Cube
Dec-25-17 09:37AM  Cellectis SA :CLLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-14-17 10:28AM  Company News For Dec 14, 2017 Zacks
Dec-13-17 04:07PM  This Biotech Stock Rocketed On Human Trials For New Cancer Drug Investor's Business Daily +11.57%
11:05AM  Why Cellectis Is Winning Big With Its Pfizer Partnership 24/7 Wall St.
Dec-12-17 06:38PM  Preliminary Data from Servier and Pfizers UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials Business Wire
Dec-04-17 04:30PM  Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer Business Wire
04:30PM  Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development Business Wire
Nov-30-17 07:40AM  Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture ACCESSWIRE
Nov-20-17 04:30PM  Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy Business Wire
Nov-15-17 11:42AM  ETFs with exposure to Cellectis SA : November 15, 2017 Capital Cube
Nov-14-17 07:00AM  Cellectis SA to Host Earnings Call ACCESSWIRE
Nov-13-17 04:15PM  Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 Business Wire
Nov-09-17 08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Nov-06-17 07:00PM  FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN Business Wire
Nov-03-17 12:03PM  ETFs with exposure to Cellectis SA : November 3, 2017 Capital Cube
Nov-01-17 04:15PM  Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting Business Wire -16.65%
04:15PM  Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting Business Wire
Oct-24-17 09:36AM  ETFs with exposure to Cellectis SA : October 24, 2017 Capital Cube
Oct-13-17 10:38AM  ETFs with exposure to Cellectis SA : October 13, 2017 Capital Cube
Oct-04-17 04:30PM  Mathieu Simon, M.D. Cellectis EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer Business Wire
Oct-02-17 03:56PM  Bluebird Bio: So Much for That Gilead Boost Barrons.com
Sep-29-17 09:04AM  Cellectis SA :CLLS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-27-17 06:54AM  Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish InvestorPlace
Sep-08-17 01:43PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A. Business Wire +6.12%
Sep-07-17 03:29PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A. Business Wire
Sep-06-17 08:29AM  Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data Zacks
Sep-05-17 05:16PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A. Business Wire -20.26%
04:47PM  Why Mallinckrodt, Universal Insurance Holdings, and Cellectis Slumped Today Motley Fool
03:45PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A. Business Wire
02:18PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellectis S.A. (CLLS) PR Newswire
02:15PM  Here's Why Cellectis SA Fell as Much as 31.6% Today Motley Fool
12:17PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS PR Newswire
08:46AM  Cellectis's stock plunges after leukemia treatment trials were put on hold MarketWatch
Sep-04-17 10:30PM  Cellectis to Participate in Upcoming Investor Conferences Business Wire
10:13PM  Cellectis Reports Clinical Hold of UCART123 Studies Business Wire
Aug-29-17 08:40AM  Cellectis (CLLS) Catches Eye: Stock Jumps 17% Zacks
Aug-28-17 11:41AM  Biotech stocks surge on Gilead's Kite Pharma acquisition MarketWatch +17.03%
Aug-17-17 04:30PM  Cellectis UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center Business Wire
Aug-02-17 04:30PM  Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 Business Wire
Jul-25-17 04:01PM  Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering Business Wire
Jul-24-17 04:30PM  Cellectis Granted Patent for CRISPR Use in T-Cells Business Wire
Jul-20-17 10:46AM  New Strong Buy Stocks for July 20th Zacks
Jul-19-17 06:51PM  Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering Business Wire
Jul-17-17 08:38AM  Strength Seen in Cellectis S.A. (CLLS): Stock Soars 8.95% Zacks
Jul-12-17 07:10AM  Featured Company News - Cellectis Announced the IPO of its Subsidiary Calyxt Accesswire
Jul-10-17 05:09PM  Move Over GMO's: IPO for Gene Editor Calyxt Launches Next Week TheStreet.com
07:06AM  Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million Business Wire
Jun-28-17 04:30PM  Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors Business Wire
Jun-27-17 04:30PM  First in Human Administration of UCART123 in Cellectis AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital Business Wire
Jun-26-17 04:30PM  Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017 Business Wire
Jun-23-17 12:45PM  Calyxt Files Registration Statement for Proposed Initial Public Offering Business Wire +6.78%
Jun-09-17 04:48PM  Cellectis: Annual General Meeting of June 26, 2017 Business Wire
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.